Editorial: What to take from TREAT

Stephen B. Hanauer

doi:10.1038/ajg.2012.224

Editorial: What to take from TREAT

Stephen B. Hanauer^*

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Review article

1 Scopus citations

Abstract

The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab-and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.

Original language	English (US)
Pages (from-to)	1423-1425
Number of pages	3
Journal	American Journal of Gastroenterology
Volume	107
Issue number	9
DOIs	https://doi.org/10.1038/ajg.2012.224
State	Published - Sep 1 2012

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1038/ajg.2012.224

Fingerprint Dive into the research topics of 'Editorial: What to take from TREAT'. Together they form a unique fingerprint.

Cite this

Hanauer, S. B. (2012). Editorial: What to take from TREAT. American Journal of Gastroenterology, 107(9), 1423-1425. https://doi.org/10.1038/ajg.2012.224

@article{67b37b0f41184c7ca8a4032a32b654af,

title = "Editorial: What to take from TREAT",

abstract = "The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab-and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.",

author = "Hanauer, {Stephen B.}",

year = "2012",

month = sep,

day = "1",

doi = "10.1038/ajg.2012.224",

language = "English (US)",

volume = "107",

pages = "1423--1425",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Editorial

T2 - What to take from TREAT

AU - Hanauer, Stephen B.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab-and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.

AB - The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab-and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=84866106496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866106496&partnerID=8YFLogxK

U2 - 10.1038/ajg.2012.224

DO - 10.1038/ajg.2012.224

M3 - Review article

C2 - 22951879

AN - SCOPUS:84866106496

VL - 107

SP - 1423

EP - 1425

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -